Skip to main content
Signal8
Launch Terminal

Invivyd, Inc. (IVVD)

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Invivyd, Inc. logo

Invivyd, Inc.

NASDAQ:IVVDHealthcare
-3.37%$0.5817
AH$0.6048+3.97%vs close
Mkt Cap$171.8M
Float246.76M
O/S295.34M
Vol
$ Vol
RVOL
Inst Own78.7%
SI15.0%
Earnings
Dilution
Invivyd, Inc. logoNASDAQ:IVVD$0.5817-3.37%
Phase Distribution
18 lead-sponsored trials·4 active·8 completed
Phase 12
Phase 21
Phase 2/32
Phase 33
Not applicable10
Status Overview
Not yet recruiting2
Recruiting1
Active, not recruiting3
Completed8
Stopped3
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

    VYD222 (pemivibart), Normal saline

    COVID-19, SARS-CoV-2

    Enrollment
    790
    Start
    Sep 2023
    Primary Completion
    Nov 2024
    Completion
    Nov 2024
    NCT06039449
  • Phase 3
    Active, not recruiting

    Study of VYD2311 for the Prevention of COVID-19

    VYD2311-SD, VYD2311-MD

    COVID-19

    Enrollment
    1,770
    Start
    Jan 2026
    Primary Completion
    Aug 2026est.
    Completion
    Aug 2026est.
    NCT07298434
  • Phase 3
    Completed

    Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

    COVID-19 mRNA vaccine, VYD2311

    COVID-19

    Enrollment
    210
    Start
    Jun 2026
    Primary Completion
    Aug 2026
    Completion
    Aug 2026
    NCT07655180
  • Phase 2/3
    Terminated

    Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

    ADG20, Normal saline

    COVID-19

    Enrollment
    399
    Start
    Jul 2021
    Primary Completion
    Feb 2022
    Completion
    Nov 2022
    NCT04805671
  • Phase 2/3
    Terminated

    Evaluation of ADG20 for the Prevention of COVID-19

    ADG20, Placebo

    COVID-19

    Enrollment
    2,582
    Start
    Apr 2021
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT04859517
  • Phase 2
    Not yet recruiting

    Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome

    VYD2311, Placebo

    Long COVID, COVID-19 (SARS-CoV-2 Infection) +2

    Enrollment
    130
    Start
    Oct 2026est.
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT07899346
  • Phase 1
    Completed

    A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants

    VYD222

    COVID-19

    Enrollment
    30
    Start
    Mar 2023
    Primary Completion
    May 2024
    Completion
    May 2024
    NCT05791318
  • Phase 1
    Active, not recruiting

    A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

    VYD2311

    COVID-19

    Enrollment
    40
    Start
    Aug 2024
    Primary Completion
    May 2025est.
    Completion
    May 2025est.
    NCT06523153
  • Not applicable
    Completed

    Prospective, Multicenter, Investigation of the Adagio Cryoablation System in Subjects With Atrial Flutter

    PolarStart System

    Atrial Flutter

    Enrollment
    17
    Start
    Jan 2015
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT02355106
  • Not applicable
    Completed

    Investigation of the Adagio Cryoablation System in Patients With Atrial Fibrillation

    Cryoablation System

    Atrial Fibrillation, Atrial Flutter

    Enrollment
    80
    Start
    Jul 2016
    Primary Completion
    Mar 2020
    Completion
    Mar 2021
    NCT02839304
  • Not applicable
    Completed

    iCLAS™ for Persistent Atrial Fibrillation

    Adagio AF Cryoablation System (iCLAS™)

    Persistent Atrial Fibrillation

    Enrollment
    215
    Start
    Dec 2019
    Primary Completion
    Aug 2023
    Completion
    Aug 2024
    NCT04061603
  • Not applicable
    Completed

    Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT)

    Ablation in the ventricles with the Adagio Medical VT Cryoablation System

    Monomorphic Ventricular Tachycardia

    Enrollment
    64
    Start
    May 2021
    Primary Completion
    Jun 2024
    Completion
    Sep 2024
    NCT04893317
  • Not applicable
    Completed

    Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLation

    Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.

    Atrial Fibrillation

    Enrollment
    89
    Start
    Oct 2022
    Primary Completion
    Oct 2024
    Completion
    Mar 2025
    NCT05408754
  • Not applicable
    Terminated

    iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

    cryoablation procedure using the iCLAS Cryoablation System

    Atrial Fibrillation, Atrial Flutter +2

    Enrollment
    91
    Start
    Sep 2021
    Primary Completion
    Jan 2025
    Completion
    Jan 2025
    NCT05416086
  • Not applicable
    Active, not recruiting

    Cryoablation for Monomorphic Ventricular Tachycardia

    cryoablation procedure

    Sustained VT

    Enrollment
    206
    Start
    Sep 2023
    Primary Completion
    Jan 2027est.
    Completion
    Mar 2027est.
    NCT05675865
  • Expanded access
    No longer available

    Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

    VYD222

    COVID-19

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT06004128
  • Not applicable
    Not yet recruiting

    VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

    VT Cryoablation System

    Ventricular Tachycardia

    Enrollment
    130
    Start
    Jan 2027est.
    Primary Completion
    May 2027est.
    Completion
    Sep 2027est.
    NCT06384599
  • Not applicable
    Recruiting

    Cryoablation for Monomorphic Ventricular Tachycardia (VTS)

    Ultra Low Temperature Ablation (ULTA)

    Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic

    Enrollment
    100
    Start
    Aug 2026
    Primary Completion
    Mar 2027est.
    Completion
    Sep 2027est.
    NCT07650032
Search ClinicalTrials.gov for “Invivyd”